# Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

> **NCT00762411** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1111 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY450139
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00762411
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 1111 (ACTUAL)
- **Last updated:** 2015-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00762411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00762411, "Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00762411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*